På baggrund af disse data er det usandsynligt, at der skulle forekomme klinisk betydende interaktioner, der involverer tenofovirdisoproxilfumarat og lægemidler, der metaboliseres af CYP450.
Based on these data, it is unlikely that clinically significant interactions involving tenofovir disoproxil fumarate and medicinal products metabolised by CYP450 would occur.